Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cholera toxin subunit B is the pentameric receptor-binding component of the AB5 holotoxin produced by Vibrio cholerae. Each B subunit (∼11 kDa) forms a doughnut-shaped pentamer that binds specifically and with high affinity to GM1 ganglioside receptors on the surface of intestinal epithelial cells[2][5]. This binding is necessary for the uptake and retrograde transport of the toxic A subunit, ultimately leading to the characteristic increase in cAMP and secretory diarrhea of cholera. CTB alone is non-toxic (lacking enzymatic activity), but it is highly immunogenic and has been widely used as a mucosal immune response stimulator, research tool for membrane trafficking, and as a carrier protein in chimeric vaccine development[1][4]. GM1 binding capacity and pentameric assembly are critical for its biological function[2].
Binds with high specificity to GM1 ganglioside on intestinal epithelial cells; mediates endocytosis and retrograde trafficking of the A subunit, enabling delivery of cytotoxic component[2][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cholera toxin subunit B (CTB).